Trigen, the biopharmaceutical company with offices in London and Munich, has reportedly hired US investment bank Piper Jaffray to advise on a potential sale or listing. UK-listed pharmaceuticals group AstraZeneca has been named as a likely bidder. Trigen's shareholders include 3i, Wellington Partners and Healthcap. A stock market listing could value Trigen at up to £100m.